anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although the association of maternal milk production with developmental programming of offspring has been investigated, there is limited information available on the relationship of maternal milk components with productive and reproductive performance of the offspring. Therefore, the present study was conducted to analyze the association of maternal milk fat and protein percentage and milk fat to protein ratio with birth weight, survival, productive and reproductive performance and AMH concentration in the offspring. In study I, data of birth weight, milk yield and reproductive variables of offspring born to lactating dams (n = 14,582) and data associated with average maternal milk fat percentage (MFP), protein percentage (MPP) and fat to protein ratio (MFPR) during 305-day lactation were retrieved. Afterwards, offspring were classified in various categories of MFP, MPP and MFPR. In study II, blood samples (n = 339) were collected from offspring in various categories of MFP, MPP and MFPR for measurement of serum AMH. Maternal milk fat percentage was positively associated with birth weight and average percentage of milk fat (APMF) and protein (APMP) and milk fat to protein ratio (FPR) during the first lactation, but negatively associated with culling rate during nulliparity in the offspring (P < 0.05). Maternal milk protein percentage was positively associated with birth weight, APMF, APMP, FPR and culling rate, but negatively associated with milk yield and fertility in the offspring (P < 0.05). Maternal FPR was positively associated with APMF and FPR, but negatively associated with culling rate, APMP and fertility in the offspring (P < 0.05). However, concentration of AMH in the offspring was not associated with MFP, MPP and MFPR (P > 0.05). In conclusion, the present study revealed that maternal milk fat and protein percentage and their ratio were associated with birth weight, survival, production and reproduction of the offspring. Yet it was a preliminary research and further studies are required to elucidate the mechanisms underlying these associations.
In an era marked by a global demographic shift towards an aging society, there is a heightened prevalence of chronic kidney disease (CKD) among older adults. The burden of CKD spans from kidney-related complications to impacting psychological well-being, giving rise to depressive symptoms and caregiver burnout. This article delves into CKD prevention strategies within the context of aging, contributing to the discourse by exploring its multifaceted aspects. The prevention of CKD in the older adults necessitates a comprehensive approach. Primary prevention is centered on the modification of risk factors, acknowledging the intricate interplay of various comorbidities. Secondary prevention focuses on early CKD identification. Tertiary prevention aims to address factors contributing to CKD progression and complications, emphasizing the importance of timely interventions. This comprehensive strategy aims to enhance the quality of life for individuals affected by CKD, decelerating the deterioration of functional status. By addressing CKD at multiple levels, this approach seeks to effectively and compassionately care for the aging population.
The invention relates to a medicine for treating chronic appendicitis, and in particular relates to a traditional Chinese medicine for treating the chronic appendicitis. The traditional Chinese medicine is prepared from is prepared from Chinese herb plants as raw materials. The traditional Chinese medicine is characterized by being prepared from the following effective components as raw medicine materials in parts by weights: 5g to 15g of rheum officinale, 4g to 13g of cortex moutan, 9g to 15g of honeysuckle, 9g to 15g of fructus forsythiae, 9g to 15g of Chinese violet, 3g to 9g of raw licorice root, 4g to 13g of costustoot, 5g to 15g of root of common peony and 25g to 35g of seed of Chinese waxgourd. All the effective components are matched and complemented with each other, so that the traditional Chinese medicine has the functions of diminishing inflammation and relieving pain, promoting the secretion of saliva and dredging collaterals, reducing fever and decreasing internal heat and the like. Based on the synergistic effects of the effective components, the traditional Chinese medicine is capable of treating both symptoms and root causes, cannot generate side effects and can be used for completely curing symptoms such as abdomen tympany, the labour pains and the dull pains of the abdomen, nausea, vomiting during pregnancy and the like. As a result, the chronic appendicitis is treated effectively.
Medial tibial stress syndrome (MTSS) is a common low leg injury. It is described as activity-induced pain along posterior medial border of leg approximately for 5 cm. Most commonly reported by runners and military personnel. Incidence of MTSS ranges between 13.6% to 20% in runners. Significant increase in loading activities or rigorous exercise causing high impact like skiping, jogging can induce MTSS which leads to stress fracture of tibia. Various risk factors are associated with the incidence of medial tibial stress syndrome which includes both intrinsic and extrinsic factors. Current study has involved comparison of therapeutic ultrasound versus shockwave therapy as there is limited knowledge about comparison of therapeutic ultrasound versus shockwave therapy.
Patients in the "AI-supported Care" arm will undergo regular follow-up at the kidney transplant center. Treating physicians will be provided an AI-based risk prediction tool that predict 1-year risk of graft loss for patients in this group based on routine parameters.
Microcapsules and composite microreactors are prepared that immunoisolate living cells such as islet cells or genetically engineered cells. A reduced volume microcapsule is formed by coating a gel matrix particle with a polyamino acid of 15,000 daltons or less molecular weight to reduce volume of the particle by at least 30% as compared to volume prior to coating. A composite microreactor includes the microcapsule containing cell embedded in a gel matrix and provides a molecular weight cutoff that prevents molecules larger than about 400,000 daltons from containing the living cell. A double composite microreactor includes an internal particle that includes an internal particle gel matrix containing a living cell and having a coating, a particle that includes the internal particle embedded in a particle gel matrix and a coating, and a gel super matrix in which the particle is embedded. At least one of the coatings is a volume reducing coating of polyamino acid of 15,000 daltons or less molecular weight. The gel matrices may be alginate, the polyamino acid may be polylysine or polyornithine, and at least one of the gel matrices or coatings may be treated by aging for between 2 hours and 14 days. The internal particle, particle and composite microreactor may have diameters respectively between 50 and 700 microns, 400 and 800 microns and 300 and 1500 microns. to be implanted so there is little or no need for immunosuppressant or antifibrotic drugs. A reduced volume microcapsule is formed by coating a gel matrix particle with a polyamino acid of 15,000 daltons or less molecular weight to reduce volume of the particle by at least 30% as compared to volume prior to coating. A composite microreactor is provided by embedding the microcapsule when containing a living cell in a gel matrix to obtain a molecular weight cutoff that prevents molecules larger than about 400,000 daltons from contacting the living cell. A double composite microreactor is formed containing an internal particle including an internal particle gel matrix containing a living cell and having a coating, a particle including the internal particle embedded in a particle gel matrix having a coating, and a gel super matrix in which the particle is embedded. At least one of the coatings is a volume reducing coating of polyamino acid of 15,000 daltons or less molecular weight. The gel matrices may be alginate, the polyamino acid may be polylysine or polyornithine, and at least one of the gel matrices or coatings may be treated by aging for between 2 hours and 14 days. The internal particle, particle and composite microreactor may have diameters respectively between 50 and 700 microns, 400 and 800 microns and 300 and 1500 microns.
PCT No. PCT/FR95/00473 Sec. 371 Date Dec. 13, 1996 Sec. 102(e) Date Dec. 13, 1996 PCT Filed Apr. 12, 1995 PCT Pub. No. WO95/27477 PCT Pub. Date Oct. 19, 1995Microspheres comprising a gelified polar core which is optionally surrounded by concentric and alternating superimposed n lipidic bilayers or n aqueous liquid layers and n gelified polar layers, n being an integer. The microspheres of the invention are obtainable by delipidation of liposomes designated as liposomes having a gelified polar core, of the type comprising at least one outer lipidic bilayer and at least one inner polar aqueous phase containing a gelified substance.
Of patients who achieved SVR, 100 inmates will be enrolled for long-term monitoring for re-infection after they have completed treatment. Patients will be seen every 6 months to test for reinfection, however they will not be subject to any medical or behavioral interventions through the study team. Limited opioid agonist therapy may be available as per the standard practice of the DOC, however syringe exchange and other harm reduction services will not be accessible to inmates, per DOC policy.
PURPOSE: To obtain a pharmaceutical preparation capable of selectively and surely releasing a pharmacodynamically effective ingredient in the colon with good reproducibility to reach the colon at a high concentration by coating a base with a polymeric substance, having a specific tensile breaking strength and decomposable in the colon. CONSTITUTION: This medicine release controlling type pharmaceutical preparation is obtained by coating a composition having a pharmacodynamically effective ingredient with a base, having 0.2-7.3kg/mm<2> tensile breaking strength and decomposable in the colon, to preferably 10-200μm thickness. For example, a copolymer comprising structural units of formulas I and II (R is a bivalent organic group; R<1> is a saccharide residue decomposed or assimilated in the colon; X<1> and X<2> are each O, imino, etc.; R<2> is a polyalkylene, a polyamide, etc.) is cited as the polymeric substance decomposable in the colon.  A copolymer in which a dibasic acid constituting the units I and II is terephthalic or isophthalic acid, a saccharide constituting the unit I is cellobiose and a polyalkylene glycol constituting the unit II is polytetramethylene glycol or polypropylene glycol is preferred as the copolymer.
The utility of intrathecal delivery is limited by the poor brain and spinal cord parenchymal uptake of intrathecally delivered agents. A simple noninvasive transcranial ultrasound protocol is provided that significantly increases the brain parenchymal uptake of intrathecally administered drugs and antibodies. This protocol of transcranial ultrasound can accelerate glymphatic fluid transport from the cisternal space into the parenchymal compartment. The low intensity and noninvasive approach of ultrasound in this protocol underscores the ready path to clinical translation of this technique. This low-intensity transcranial ultrasound protocol can be used to directly bypass the blood-brain barrier for whole-brain delivery of a variety of agents. Additionally, this protocol is useful as a means to probe the causal role of the glymphatic system in the variety of disease and physiologic processes to which it has been correlated.
BACKGROUND: There is a paucity of literature evaluating long-term outcomes and survivorship of patients undergoing primary hip arthroscopy with capsular repair for femoroacetabular impingement syndrome (FAIS).
PURPOSE: To report 10-year survivorship and patient-reported outcomes (PROs) after primary hip arthroscopy with capsular repair for FAIS and evaluate the effect of capsular repair in patients at the highest risk for conversion to arthroplasty.
STUDY DESIGN: Cohort study; Level of evidence, 3.
METHODS: Data were prospectively collected and retrospectively reviewed on all patients undergoing primary hip arthroscopy with capsular repair between October 2008 and February 2011. Patients with a minimum 10-year follow-up on the modified Harris Hip Score (mHHS), Nonarthritic Hip Score (NAHS), and visual analog scale for pain (VAS) scores were selected. The preoperative and minimum 10-year follow-up Hip Outcome Score-Sports Specific Subscale (HOS-SSS) scores were also reported, if available. Patients with ipsilateral hip surgery, worker's compensation, Tönnis osteoarthritis grade >1, and hip dysplasia (lateral center-edge angle <25°) were excluded. Survivorship, PROS, and clinical benefit-minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS)-were reported. An additional propensity-matched subanalysis was performed on patients at the highest risk for conversion to arthroplasty, comparing patients undergoing capsular repair to patients with unrepaired capsules.
RESULTS: A total of 145 (n = 130 patients) out of 180 eligible hips (n = 165 patients) had a minimum 10-year follow-up (80.6%). Also, 126 hips (86.9%) belonged to women, and 19 hips (13.1%) belonged to men. The mean patient age was 30.3 ± 12.9 years. The survivorship rate was 91% at the 10-year follow-up. The cohort experienced significant improvements (P < .001) in the mHHS, NAHS, HOS-SSS, and VAS for pain scores. Moreover, the cohort achieved high rates of the PASS for the mHHS (89.8%), high rates of the MCID for the mHHS (82.4%), and high rates of the MCID for VAS for pain (80.6%) scores. In the propensity-matched subanalysis performed on patients with the highest risk for arthroplasty, 29 hips with capsular repair were matched to 81 hips with unrepaired capsules. While both groups experienced significant improvements in all PROs (P < .05), the group without capsule repair trended toward a higher conversion to arthroplasty rate when compared with the repair group. In addition, an odds ratio was calculated for the likelihood of converting to arthroplasty after having an unrepaired capsule compared with capsular repair (2.54 [95% CI, 0.873-7.37]; P = .087).
CONCLUSION: Patients undergoing primary hip arthroscopy with capsular repair experienced a high survivorship rate of 91% at a minimum 10-year follow-up. Patients who did not convert to arthroplasty saw favorable improvements in PROs and achieved high clinical benefit rates. In addition, among those patients at the highest risk for conversion to arthroplasty, a trend toward greater survivorship was observed with capsular repair.
Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution. Methylene Blue(1 mg/kg/IBW iv over 30min+0.25mg/kg/h x 6h) x 5-days/ discontinution of norepinephrine /ICU discharge (whichever occurred first).
PURPOSE:To obtain the solidified body of an immune body having a high sensitivity by allowing an amino acid compd. to exist at the time of integrally solidifying the immune body by a hydrophilic polymer. CONSTITUTION:The immune body, the hydrophilic polymer and the amino acid compd. are stirred and dissolved in an aq. solvent and the soln. is applied to the proper area on a carrier. The coating is subjected to treatments with alcohol, block agent, etc., and is finally dried, by which the solidified body of the immune body having the high sensitivity is obtd. The immune body is various antigens or antibodies. The hydrophilic polymer is cellulose resins, such as methyl cellulose, which are used alone or as a mixture composed of >=2 kinds thereof. The amino acid compd. is a compd. (low mol. wt. amino acid polymer) formed by peptide bonding of >=2 amino acids and is adequately the compd. formed by the peptide bonding of usually 2 to 100 pieces, more preferably 4 to 70 pieces and further preferably 15 to 50 pieces amino acids. The carrier for solidificaion is preferably a porous membrane, etc., of a large specific surface area. The drying is executed preferably by freeze drying and the immune body solidified in this way is further stably preserved.
BACKGROUND: The purpose of this study was to determine the influence of chronic preoperative opioid use on complications, reoperation rates, and postoperative opioid use among patients undergoing open reduction and internal fixation (ORIF) of distal radius fractures.
METHODS: A retrospective review of 111 patients who underwent ORIF of a distal radius fracture from 2019 to 2021 at an academic medical center by the same fellowship-trained orthopedic hand surgeon was conducted. Patient demographics, medical comorbidities, perioperative details, surgical complications, and patient-reported outcome measures were analyzed. The SCRIPTS database was used to obtain opioid prescription data.
RESULTS: A total of 10 patients (9.01%) were identified as preoperative chronic opioid users. This group was not associated with risk of increased complication. However, they were more likely to continue using narcotics at 90 and 180 days postoperatively. Patients with a history of substance use were at an increased risk of hardware complications and prolonged postoperative pain. In addition, these patients were more likely to receive narcotics at 90 and 180 days, and to have more refills postoperatively.
CONCLUSION: Patients with preoperative opioid use are not at an increased risk of surgical complication following ORIF of distal radius fractures. However, they are at an increased risk of prolonged postoperative opioid use. Patients with a known history of substance use were at an increased risk of hardware complications, prolonged pain, and increased postoperative opioid use. Surgeons should consider these associations to better manage individual patients in the postoperative period.
Bacteriostatic deodorant compsns. for body hygiene contains >=1 (1-5) wt.% bactericidal hop extract, as active ingredient for eliminating or masking body odour caused by Gram positive sweat-decomposing bacteria. The deodorant can be used as soap or stick (preferred), or a liquid, lotion, atomised liquid, cream, powder or oil. Body odour-causing bacteria, e.g. Staphylococcus aureus and Staphylococcus epidermis, are effectively inhibited on using compsns. contg. as little as 1% hop extract. The hop extract is non-toxic, miscible with other cosmetic ingredients and does not irritate the skin.
A 45-minute session, hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
Spontaneous intracerebral hemorrhage (ICH) is a type of stroke less prevalent than ischemic stroke but associated with high mortality rates. Hematoma expansion (HE) is an increase in the bleeding that affects 30%-38% of hemorrhagic stroke patients. It is observed within 24 h of onset and associated with patient worsening. Clinically it is relevant to detect the patients that will develop HE from their initial computed tomography (CT) scans which could improve patient management and treatment decisions. However, this is a significant challenge due to the predictive nature of the task and its low prevalence, which hinders the availability of large datasets with the required longitudinal information. In this work, we present an end-to-end deep learning framework capable of predicting which cases will exhibit HE using only the initial basal image. We introduce a deep learning framework based on the 2D EfficientNet B0 model to predict the occurrence of HE using initial non-contrasted CT scans and their corresponding lesion annotation as priors. We used an in-house acquired dataset of 122 ICH patients, including 35 HE cases, containing longitudinal CT scans with manual lesion annotations in both basal and follow-up (obtained within 24 h after the basal scan). Experiments were conducted using a 5-fold cross-validation strategy. We addressed the limited data problem by incorporating synthetic images into the training process. To the best of our knowledge, our approach is novel in the field of HE prediction, being the first to use image synthesis to enhance results. We studied different scenarios such as training only with the original scans, using standard image augmentation techniques, and using synthetic image generation. The best performance was achieved by adding five generated versions of each image, along with standard data augmentation, during the training process. This significantly improved (p=0.0003) the performance obtained with our baseline model using directly the original CT scans from an Accuracy of 0.56 to 0.84, F1-Score of 0.53 to 0.82, Sensitivity of 0.51 to 0.77, and Specificity of 0.60 to 0.91, respectively. The proposed approach shows promising results in predicting HE, especially with the inclusion of synthetically generated images. The obtained results highlight the significance of this research direction, which has the potential to improve the clinical management of patients with hemorrhagic stroke. The code is available at: https://github.com/NIC-VICOROB/HE-prediction-SynthCT.
Kawasaki disease (KD) in its acute phase produces endothelial inflammation that can lead to dilatation and aneurysms of coronary and peripheral arteries. This initial injury leads to persistent endothelial dysfunction several years after having the disease. As a consequence, these patients may have a higher cardiovascular risk than general population. Studies with HMG-CoA reductase inhibitors (statins) have suggested that these have an anti-inflammatory effect over the endothelium, that may be independent of its lipid-lowering effects. The hypothesis of this study is that KD produces endothelial dysfunction that is persistent years after acute disease, and that this dysfunction can be modified by treatment with statins.The study consists of two phases. On the first we will perform ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery and evaluate other cardiovascular risk markers in patients and healthy controls. On the second phase patients with history of Kawasaki disease will be randomized and allocated to treatment with Pravastatin or placebo, after which a new evaluation of flow-mediated dilation of the brachial artery and cardiovascular risk markers will be performed.

Comparison(s): Children older than 8 years of age with history of Kawasaki disease more than 12 months before enrollment, compared with paired by age children without history of KD or other cardiovascular risk factors.